> top > docs > PubMed:17158762 > annotations

PubMed:17158762 JSONTXT

Annnotations TAB JSON ListView MergeView

PMID_GLOBAL

Id Subject Object Predicate Lexical cue mondo_id
T1 0-29 DiseaseOrPhenotypicFeature denotes Differentiated thyroid cancer 0015447
T2 195-209 DiseaseOrPhenotypicFeature denotes thyroid cancer 0002108|0015075
T4 326-340 DiseaseOrPhenotypicFeature denotes thyroid cancer 0002108|0015075
T6 432-466 DiseaseOrPhenotypicFeature denotes Papillary and follicular carcinoma 0006886
T7 888-902 DiseaseOrPhenotypicFeature denotes thyroid cancer 0002108|0015075
T9 1411-1436 DiseaseOrPhenotypicFeature denotes follicular thyroid cancer 0005034
T10 1696-1714 DiseaseOrPhenotypicFeature denotes thyroid carcinomas 0015075

DisGeNET

Id Subject Object Predicate Lexical cue
T0 65-97 gene:1956 denotes epidermal growth factor receptor
T1 0-29 disease:C1337013 denotes Differentiated thyroid cancer
T2 275-307 gene:1956 denotes epidermal growth factor receptor
T3 326-340 disease:C0007115 denotes thyroid cancer
T4 275-307 gene:1956 denotes epidermal growth factor receptor
T5 326-340 disease:C0549473 denotes thyroid cancer
T6 309-313 gene:1956 denotes EGFR
T7 326-340 disease:C0549473 denotes thyroid cancer
T8 309-313 gene:1956 denotes EGFR
T9 326-340 disease:C0007115 denotes thyroid cancer
T10 861-864 gene:1950 denotes EGF
T11 888-902 disease:C0007115 denotes thyroid cancer
T12 861-864 gene:1950 denotes EGF
T13 888-902 disease:C0549473 denotes thyroid cancer
R1 T0 T1 associated_with epidermal growth factor receptor,Differentiated thyroid cancer
R2 T2 T3 associated_with epidermal growth factor receptor,thyroid cancer
R3 T4 T5 associated_with epidermal growth factor receptor,thyroid cancer
R4 T6 T7 associated_with EGFR,thyroid cancer
R5 T8 T9 associated_with EGFR,thyroid cancer
R6 T10 T11 associated_with EGF,thyroid cancer
R7 T12 T13 associated_with EGF,thyroid cancer

PubmedHPO

Id Subject Object Predicate Lexical cue
T1 203-209 HP_0002664 denotes cancer
T2 334-340 HP_0002664 denotes cancer
T3 896-902 HP_0002664 denotes cancer
T4 1430-1436 HP_0002664 denotes cancer
T5 1685-1695 HP_0000718 denotes aggressive
T6 1696-1714 HP_0002890 denotes thyroid carcinomas
T1 203-209 HP_0002664 denotes cancer
T2 334-340 HP_0002664 denotes cancer
T3 896-902 HP_0002664 denotes cancer
T4 1430-1436 HP_0002664 denotes cancer
T5 1685-1695 HP_0000718 denotes aggressive
T6 1696-1714 HP_0002890 denotes thyroid carcinomas

DisGeNET5_gene_disease

Id Subject Object Predicate Lexical cue
17158762-0#65#97#gene1956 65-97 gene1956 denotes epidermal growth factor receptor
17158762-0#155#167#gene4313 155-167 gene4313 denotes gelatinase A
17158762-0#0#29#diseaseC1337013 0-29 diseaseC1337013 denotes Differentiated thyroid cancer
17158762-2#39#71#gene1956 275-307 gene1956 denotes epidermal growth factor receptor
17158762-2#73#77#gene1956 309-313 gene1956 denotes EGFR
17158762-2#90#104#diseaseC0007115 326-340 diseaseC0007115 denotes thyroid cancer
17158762-2#90#104#diseaseC0549473 326-340 diseaseC0549473 denotes thyroid cancer
17158762-2#90#104#diseaseC0007115 326-340 diseaseC0007115 denotes thyroid cancer
17158762-2#90#104#diseaseC0549473 326-340 diseaseC0549473 denotes thyroid cancer
17158762-3#64#67#gene1950 496-499 gene1950 denotes EGF
17158762-3#0#34#diseaseC0206683 432-466 diseaseC0206683 denotes Papillary and follicular carcinoma
17158762-6#0#3#gene1950 861-864 gene1950 denotes EGF
17158762-6#183#201#gene388007 1044-1062 gene388007 denotes protease inhibitor
17158762-6#27#41#diseaseC0007115 888-902 diseaseC0007115 denotes thyroid cancer
17158762-6#27#41#diseaseC0549473 888-902 diseaseC0549473 denotes thyroid cancer
17158762-6#27#41#diseaseC0007115 888-902 diseaseC0007115 denotes thyroid cancer
17158762-6#27#41#diseaseC0549473 888-902 diseaseC0549473 denotes thyroid cancer
65#97#gene19560#29#diseaseC1337013 17158762-0#65#97#gene1956 17158762-0#0#29#diseaseC1337013 associated_with epidermal growth factor receptor,Differentiated thyroid cancer
155#167#gene43130#29#diseaseC1337013 17158762-0#155#167#gene4313 17158762-0#0#29#diseaseC1337013 associated_with gelatinase A,Differentiated thyroid cancer
39#71#gene195690#104#diseaseC0007115 17158762-2#39#71#gene1956 17158762-2#90#104#diseaseC0007115 associated_with epidermal growth factor receptor,thyroid cancer
39#71#gene195690#104#diseaseC0549473 17158762-2#39#71#gene1956 17158762-2#90#104#diseaseC0549473 associated_with epidermal growth factor receptor,thyroid cancer
39#71#gene195690#104#diseaseC0007115 17158762-2#39#71#gene1956 17158762-2#90#104#diseaseC0007115 associated_with epidermal growth factor receptor,thyroid cancer
39#71#gene195690#104#diseaseC0549473 17158762-2#39#71#gene1956 17158762-2#90#104#diseaseC0549473 associated_with epidermal growth factor receptor,thyroid cancer
73#77#gene195690#104#diseaseC0007115 17158762-2#73#77#gene1956 17158762-2#90#104#diseaseC0007115 associated_with EGFR,thyroid cancer
73#77#gene195690#104#diseaseC0549473 17158762-2#73#77#gene1956 17158762-2#90#104#diseaseC0549473 associated_with EGFR,thyroid cancer
73#77#gene195690#104#diseaseC0007115 17158762-2#73#77#gene1956 17158762-2#90#104#diseaseC0007115 associated_with EGFR,thyroid cancer
73#77#gene195690#104#diseaseC0549473 17158762-2#73#77#gene1956 17158762-2#90#104#diseaseC0549473 associated_with EGFR,thyroid cancer
64#67#gene19500#34#diseaseC0206683 17158762-3#64#67#gene1950 17158762-3#0#34#diseaseC0206683 associated_with EGF,Papillary and follicular carcinoma
0#3#gene195027#41#diseaseC0007115 17158762-6#0#3#gene1950 17158762-6#27#41#diseaseC0007115 associated_with EGF,thyroid cancer
0#3#gene195027#41#diseaseC0549473 17158762-6#0#3#gene1950 17158762-6#27#41#diseaseC0549473 associated_with EGF,thyroid cancer
0#3#gene195027#41#diseaseC0007115 17158762-6#0#3#gene1950 17158762-6#27#41#diseaseC0007115 associated_with EGF,thyroid cancer
0#3#gene195027#41#diseaseC0549473 17158762-6#0#3#gene1950 17158762-6#27#41#diseaseC0549473 associated_with EGF,thyroid cancer
183#201#gene38800727#41#diseaseC0007115 17158762-6#183#201#gene388007 17158762-6#27#41#diseaseC0007115 associated_with protease inhibitor,thyroid cancer
183#201#gene38800727#41#diseaseC0549473 17158762-6#183#201#gene388007 17158762-6#27#41#diseaseC0549473 associated_with protease inhibitor,thyroid cancer
183#201#gene38800727#41#diseaseC0007115 17158762-6#183#201#gene388007 17158762-6#27#41#diseaseC0007115 associated_with protease inhibitor,thyroid cancer
183#201#gene38800727#41#diseaseC0549473 17158762-6#183#201#gene388007 17158762-6#27#41#diseaseC0549473 associated_with protease inhibitor,thyroid cancer

DisGeNet-2017-sample

Id Subject Object Predicate Lexical cue
T2344 861-864 gene:1950 denotes EGF
T2345 888-902 disease:C0007115 denotes thyroid cancer
T2346 1044-1062 gene:388007 denotes protease inhibitor
R1 T2344 T2345 associated_with EGF,thyroid cancer
R2 T2344 T2345 associated_with EGF,thyroid cancer
R3 T2346 T2345 associated_with protease inhibitor,thyroid cancer
R4 T2346 T2345 associated_with protease inhibitor,thyroid cancer

sentences

Id Subject Object Predicate Lexical cue
TextSentencer_T1 0-168 Sentence denotes Differentiated thyroid cancer cell invasion is regulated through epidermal growth factor receptor-dependent activation of matrix metalloproteinase (MMP)-2/gelatinase A.
TextSentencer_T2 169-235 Sentence denotes Mechanisms of invasion in thyroid cancer remain poorly understood.
TextSentencer_T3 236-431 Sentence denotes We hypothesized that signaling via the epidermal growth factor receptor (EGFR) stimulates thyroid cancer cell invasion by altering the expression and cleavage of matrix metalloproteinases (MMPs).
TextSentencer_T4 432-585 Sentence denotes Papillary and follicular carcinoma cell lines were treated with EGF, the EGFR tyrosine kinase inhibitor AG1478, and the MMP inhibitors GM-6001 and Col-3.
TextSentencer_T5 586-625 Sentence denotes Flow cytometry was used to detect EGFR.
TextSentencer_T6 626-802 Sentence denotes In vitro invasion assays, gelatin zymography, and quantitative reverse transcription-PCR were used to assess the changes in invasive behavior and MMP expression and activation.
TextSentencer_T7 803-860 Sentence denotes All cell lines were found to overexpress functional EGFR.
TextSentencer_T8 861-1073 Sentence denotes EGF stimulated invasion by thyroid cancer cells up to sevenfold (P<0.0001), a process that was antagonized completely by AG1478 and Col-3, partially by GM-6001, but not by the serine protease inhibitor aprotinin.
TextSentencer_T9 1074-1205 Sentence denotes EGF upregulated expression of MMP-9 (2.64- to 8.89-fold, P<0.0001) and membrane type-1 MMP (MT1-MMP, 1.97- to 2.67-fold, P<0.0001).
TextSentencer_T10 1206-1274 Sentence denotes This effect was blocked completely by AG1478 and partially by Col-3.
TextSentencer_T11 1275-1329 Sentence denotes The activation of MMP-2 paralleled MT1-MMP expression.
TextSentencer_T12 1330-1456 Sentence denotes We demonstrate that MMPs are critical effectors of invasion in the papillary and follicular thyroid cancer cell lines studied.
TextSentencer_T13 1457-1581 Sentence denotes Invasion is regulated by signaling through EGFR, an effect mediated by augmentation of gelatinase expression and activation.
TextSentencer_T14 1582-1715 Sentence denotes MMP inhibitors and growth factor antagonists may be effective tumoristatic agents for the treatment of aggressive thyroid carcinomas.
T1 0-168 Sentence denotes Differentiated thyroid cancer cell invasion is regulated through epidermal growth factor receptor-dependent activation of matrix metalloproteinase (MMP)-2/gelatinase A.
T2 169-235 Sentence denotes Mechanisms of invasion in thyroid cancer remain poorly understood.
T3 236-431 Sentence denotes We hypothesized that signaling via the epidermal growth factor receptor (EGFR) stimulates thyroid cancer cell invasion by altering the expression and cleavage of matrix metalloproteinases (MMPs).
T4 432-585 Sentence denotes Papillary and follicular carcinoma cell lines were treated with EGF, the EGFR tyrosine kinase inhibitor AG1478, and the MMP inhibitors GM-6001 and Col-3.
T5 586-625 Sentence denotes Flow cytometry was used to detect EGFR.
T6 626-802 Sentence denotes In vitro invasion assays, gelatin zymography, and quantitative reverse transcription-PCR were used to assess the changes in invasive behavior and MMP expression and activation.
T7 803-860 Sentence denotes All cell lines were found to overexpress functional EGFR.
T8 861-1073 Sentence denotes EGF stimulated invasion by thyroid cancer cells up to sevenfold (P<0.0001), a process that was antagonized completely by AG1478 and Col-3, partially by GM-6001, but not by the serine protease inhibitor aprotinin.
T9 1074-1205 Sentence denotes EGF upregulated expression of MMP-9 (2.64- to 8.89-fold, P<0.0001) and membrane type-1 MMP (MT1-MMP, 1.97- to 2.67-fold, P<0.0001).
T10 1206-1274 Sentence denotes This effect was blocked completely by AG1478 and partially by Col-3.
T11 1275-1329 Sentence denotes The activation of MMP-2 paralleled MT1-MMP expression.
T12 1330-1456 Sentence denotes We demonstrate that MMPs are critical effectors of invasion in the papillary and follicular thyroid cancer cell lines studied.
T13 1457-1581 Sentence denotes Invasion is regulated by signaling through EGFR, an effect mediated by augmentation of gelatinase expression and activation.
T14 1582-1715 Sentence denotes MMP inhibitors and growth factor antagonists may be effective tumoristatic agents for the treatment of aggressive thyroid carcinomas.